Cue Biopharma shares jump 15.22% intraday after licensing Immuno-STAT technology to ImmunoScape for cancer immunotherapy collaboration.

Cue Biopharma surged 15.22% intraday following an exclusive licensing agreement with ImmunoScape to develop a "Seed-and-Boost" immunotherapy for solid tumors, combining Cue’s Immuno-STAT molecules with ImmunoScape’s TCR technology. The partnership, highlighted by leadership appointments including Cue’s new CEO Usman Azam and strategic focus on autoimmune disease treatments, aligns with a Lucid Capital Markets buy rating and $4.00 price target. Analysts cited the collaboration’s potential to address oncology challenges, preclinical progress targeting the WT1 antigen, and validation from Nobel Prize-aligned discoveries in Cue’s CUE-401 program. Despite Cue’s cash burn concerns, the deal and bullish analyst sentiment drove immediate investor optimism.